Figure 4 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors

Schematic depicting proteins and pathways differently regulated in capivasertib-resistant cancers, as observed in patient tumors and breast cancer cell lines. Proteins with expression changes confirmed (FC > 1.3; P < 0.1) by MRM-MS data in cell lines are shown in red (increased), dark gray (no change), and green (decreased). Proteins with expression data from LFQ in patient tumor samples are shown in dark orange (increased) and dark blue (decreased). Light orange (activated) and light blue (inhibited) indicate proteins with predicted activity changes based on pathway analysis of the LFQ data. Proteins with no expression data are shown in light gray. (Figure Created with BioRender.com.)